Eiger BioPharmaceuticals Long Term Debt

Eiger BioPharmaceuticals (EIGR) currently reports a long-term debt of $0 as of December 2023. That compares with $40M in the prior-year period — down 100.0% year over year. Use the charts on this page to explore Eiger BioPharmaceuticals's long-term debt history and peer comparisons.

Eiger BioPharmaceuticals's long-term debt decreased from $40M to $0 — a 100.0% year-over-year decrease (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Eiger BioPharmaceuticals reported $0 in long-term debt as of December 2023. That compares with $40M in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Eiger BioPharmaceuticals, and consider following EIGR for alerts when major investors trade the stock.

Eiger BioPharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EIGR with unrelated industries.